Monashee Investment Management LLC Sells 741,135 Shares of Compass Therapeutics, Inc. $CMPX

Key Points

• Monashee Investment Management cut its Compass Therapeutics stake by 74.1% in the first quarter, selling 741,135 shares and leaving it with 258,865 shares worth about $1.37 million.
• Other institutions were active in the stock as well, with firms like Dimensional Fund Advisors and Y Intercept Hong Kong increasing holdings; institutional investors now own 68.43% of Compass Therapeutics.
• Analysts remain generally positive on CMPX, with a consensus rating of “Moderate Buy” and an average price target of $12.25, even though the stock was trading around $2.04 and the company recently reported earnings in line with expectations.

Monashee Investment Management LLC trimmed its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 74.1% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 258,865 shares of the company's stock after selling 741,135 shares during the quarter. Monashee Investment Management LLC owned 0.14% of Compass Therapeutics worth $1,369,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the company. PNC Financial Services Group Inc. lifted its holdings in shares of Compass Therapeutics by 2,572.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 11,038 shares of the company's stock worth $58,000 after acquiring an additional 10,625 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Compass Therapeutics by 28.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 439,784 shares of the company's stock valued at $2,324,000 after purchasing an additional 98,188 shares during the last quarter. Swiss National Bank bought a new position in Compass Therapeutics during the 1st quarter valued at about $1,168,000. Independent Financial Group LLC purchased a new stake in Compass Therapeutics in the 1st quarter worth about $121,000. Finally, Y Intercept Hong Kong Ltd raised its position in Compass Therapeutics by 79.3% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 828,879 shares of the company's stock worth $4,385,000 after purchasing an additional 366,713 shares during the period. Institutional investors own 68.43% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on CMPX. HC Wainwright restated a "buy" rating and set a $24.00 target price on shares of Compass Therapeutics in a research report on Monday, April 27th. Canaccord Genuity Group decreased their price target on Compass Therapeutics from $13.00 to $7.00 and set a "buy" rating for the company in a research note on Tuesday, April 28th. Stifel Nicolaus set a $6.00 price objective on Compass Therapeutics in a report on Monday, June 1st. Citigroup reiterated a "market outperform" rating on shares of Compass Therapeutics in a research note on Thursday, June 4th. Finally, D. Boral Capital reiterated a "buy" rating and set a $30.00 target price on shares of Compass Therapeutics in a research report on Monday, April 27th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $12.25.

Compass Therapeutics Stock Performance

Shares of NASDAQ:CMPX opened at $2.04 on Thursday. The firm has a market cap of $367.38 million, a PE ratio of -4.98 and a beta of 0.90. The firm's 50 day simple moving average is $2.11 and its 200-day simple moving average is $4.14. Compass Therapeutics, Inc. has a one year low of $1.61 and a one year high of $6.88.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.10). Equities research analysts predict that Compass Therapeutics, Inc. will post -0.42 EPS for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.